Pfizer International Collaboration Issues
Download
Report
Transcript Pfizer International Collaboration Issues
Issues for Personalized Medicine In
California’s Regulatory Environment
Issues for Personalized Medicine In California’s
Regulatory Environment
Confidentiality of Medical Information Act (CMIA)
“Safe Harbor” for consented tissue and data
Discrimination protections beyond GINA
State personnel certification requirements
Confidential Medical Information Act
CMIA, Cal Civil Code 56 et seq,
– Cumbersome
– Without relevant exceptions
– use and sharing of data
– enable Health Information Technology
– secondary use of data
Safe Harbor for use of samples and consent
Current law and interpretation
– Prohibits study of previously consented samples & data
Adoption of appropriate safe harbor provisions
– Consent should spur research & technology advancement
– Protect privacy
– Allow “tracking without tracing”
Discrimination Laws not broad enough
GINA prohibits discrimination
– Heredity and genetic predisposition only
– Fails to protect if condition is not “genetic”
California could offer broader protection
– Mandate for coverage and community rating insurance
Unique CA Personnel Certification
Requirements
Lab testing must be by certified personnel
Significant shortfall in certified personnel
– In 2001, California had 76 CLS per 100,000
– 102 nationally
– CA ranked 43rd among the states
Significant shortfall of programs for certification
– 2007 report CA: needed 800 new CLSs a year.
– 559% increase